{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:23:54Z","timestamp":1747232634617,"version":"3.40.5"},"reference-count":36,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["biomedica"],"abstract":"<jats:p>Introducci\u00f3n. El hipertiroidismo es una condici\u00f3n heterog\u00e9nea caracterizada por la producci\u00f3n excesiva de hormonas tiroideas. Su aparici\u00f3n en la edad pedi\u00e1trica representa un reto diagn\u00f3stico y terap\u00e9utico.Objetivo. Describir las caracter\u00edsticas cl\u00ednicas y paracl\u00ednicas, as\u00ed como la evoluci\u00f3n y las diferencias entre las principales causas etiol\u00f3gicas de los pacientes con hipertiroidismo atendidos por el Servicio de Endocrinolog\u00eda Pedi\u00e1trica del Hospital Universitario San Vicente Fundaci\u00f3n en Medell\u00edn, Colombia, entre el 1\u00b0 de julio de 2015 y el 30 de junio de 2020. Materiales y m\u00e9todos. Se hizo un estudio observacional transversal con recolecci\u00f3n retrospectiva de la informaci\u00f3n.Resultados. Se incluyeron 54 pacientes con una edad media de 11,9 a\u00f1os, 72,2 % de ellos mujeres. El 11,1 % ten\u00eda antecedentes familiares de enfermedad de Graves y 29,6 % de otras enfermedades tiroideas. El bocio fue la manifestaci\u00f3n cl\u00ednica m\u00e1s frecuente (83,3 %). El 92,6 % hab\u00eda recibido terapia con metimazol, el 79,6 % requiri\u00f3 betabloqueador y el 11,2 % necesit\u00f3 una terapia farmacol\u00f3gica adicional. Se presentaron reacciones adversas a la medicaci\u00f3n en el 16,7 %. En el 20,4 % de los pacientes hubo resoluci\u00f3n del hipertiroidismo (espont\u00e1nea: 9,3 %; posterior a la ablaci\u00f3n con yodo radiactivo: 9,3 %, y despu\u00e9s de la cirug\u00eda: 1,9 %).Conclusi\u00f3n. El hipertiroidismo es una enfermedad con manifestaciones cl\u00ednicas diversas. La causa m\u00e1s frecuente es la enfermedad de Graves, seguida por la hashitoxicosis. En este estudio, la hashitoxicosis fue m\u00e1s frecuente que en estudios previos. La duraci\u00f3n y los efectos secundarios del tratamiento farmacol\u00f3gico fueron similares a los reportados previamente, pero es de resaltar la mayor frecuencia de agranulocitosis en nuestra poblaci\u00f3n.<\/jats:p>","DOI":"10.7705\/biomedica.6244","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T17:01:11Z","timestamp":1657731671000},"page":"342-354","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Hipertiroidismo en ni\u00f1os y adolescentes: experiencia en un hospital universitario en Colombia"],"prefix":"10.7705","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-1712","authenticated-orcid":false,"given":"Judith Sof\u00eda","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-2114","authenticated-orcid":false,"given":"Mar\u00eda Paula","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-2126","authenticated-orcid":false,"given":"Jes\u00fas David","family":"Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-3286","authenticated-orcid":false,"given":"Nora Alejandra","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-8443","authenticated-orcid":false,"given":"Adriana Carolina","family":"Forero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7650-6057","authenticated-orcid":false,"given":"Laura Fernanda","family":"Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"109332","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Carel JC. Hyperthyroidism in childhood: Causes, when and how to treat. J Clin Res Pediatr Endocrinol. 2013;5(Suppl.1):50-6. https:\/\/doi.org\/10.4274\/jcrpe.854","DOI":"10.4274\/jcrpe.854"},{"key":"109333","doi-asserted-by":"crossref","unstructured":"Mokhashi MH, Desai U, Desai MP. Hyperthyroidism in children. Indian J Pediatr. 2000;67:653-6. https:\/\/doi.org\/10.1007\/BF02762177","DOI":"10.1007\/BF02762177"},{"key":"109334","doi-asserted-by":"crossref","unstructured":"Srinivasan S. Hyperthyroidism in children. Pediatr Rev. 2015;36:239-48. https:\/\/doi.org\/10.1542\/pir.36-6-239","DOI":"10.1542\/pir.36.6.239"},{"key":"109335","doi-asserted-by":"crossref","unstructured":"Marino M, Vitti P, Chiovato L. Graves\u2019 disease. En: Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, et al., editors. Endocrinology: adult and pediatric. Seventh edition. Philadelphia: Saunders; 2015. p. 1437-64.e8 p. https:\/\/doi.org\/10.1016\/B978-0-323-18907-1.00082-2","DOI":"10.1016\/B978-0-323-18907-1.00082-2"},{"key":"109336","doi-asserted-by":"crossref","unstructured":"Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents: A review. JAMA Pediatr. 2016;170:1008-19. https:\/\/doi.org\/10.1001\/jamapediatrics.2016.0486","DOI":"10.1001\/jamapediatrics.2016.0486"},{"key":"109337","unstructured":"Alvira J, Galv\u00e1n G, Ord\u00f3\u00f1ez J. Eficacia y seguridad del metimazol en el tratamiento del hipertiroidismo por enfermedad de Graves en menores de 18 a\u00f1os: Barranquilla, 2013-2015. Biociencias. 2016;11:41-7."},{"key":"109338","unstructured":"Laboratory Corporation of America. Expected Values & S.I. Unit Conversion Tables. Esoterix. 2017. Fecha de consulta: 2 de junio de 2022. Disponible en: https:\/\/specialtytesting.labcorp.com\/sites\/default\/files\/2021-07\/L5167-0421-18%20Endocrine%20Expected%20Values_0.pdf"},{"key":"109339","doi-asserted-by":"crossref","unstructured":"Godoy CC, Acevedo MM, Barrera NA, Yismeyi\u00e1n MA, Ugarte PF. Hipertiroidismo en ni\u00f1os y adolescentes. Rev Chil Pediatr. 2009;80:21-9. https:\/\/doi.org\/10.4067\/S0370-41062009000100003","DOI":"10.4067\/S0370-41062009000100003"},{"key":"109340","doi-asserted-by":"crossref","unstructured":"Simon M, Rigou A, Le Moal J, Zeghnoun A, Le Tertre A, De Crouy-Chanel P, et al. Epidemiology of childhood hyperthyroidism in France: A nationwide population-based study. J Clin Endocrinol Metab. 2018;103:2980-7. https:\/\/doi.org\/10.1210\/jc.2018-00273","DOI":"10.1210\/jc.2018-00273"},{"key":"109341","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Oliver I, Rodrigue D, Lambert AS, Coutant R. Graves\u2019 disease in children. Ann Endocrinol (Paris). 2018;79:647-55. https:\/\/doi.org\/10.1016\/j.ando.2018.08.001","DOI":"10.1016\/j.ando.2018.08.001"},{"key":"109342","doi-asserted-by":"crossref","unstructured":"Kyritsi EM, Kanaka-Gantenbein C. Autoimmune thyroid disease in specific genetic syndromes in childhood and adolescence. Front Endocrinol (Lausanne). 2020;11:543. https:\/\/doi.org\/10.3389\/fendo.2020.00543","DOI":"10.3389\/fendo.2020.00543"},{"key":"109343","doi-asserted-by":"crossref","unstructured":"Rodanaki M, Lodefalk M, Forssell K, Arvidsson CG, Forssberg M, \u00c5man J. The incidence of childhood thyrotoxicosis is increasing in both girls and boys in Sweden. Horm Res Paediatr. 2019;91:195-202. https:\/\/doi.org\/10.1159\/000500265","DOI":"10.1159\/000500265"},{"key":"109344","doi-asserted-by":"crossref","unstructured":"Havgaard Kj\u00e6r R, Smedeg\u00e5rd Andersen M, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark: A nationwide study, 1998-2012. Horm Res Paediatr. 2015;84:102-7. https:\/\/doi.org\/10.1159\/000430985","DOI":"10.1159\/000430985"},{"key":"109345","doi-asserted-by":"crossref","unstructured":"Zanolli M, Araya A, Cattani A, Orellana P, Mart\u00ednez-Aguayo A. Enfermedad de Basedow Graves en pacientes pedi\u00e1tricos. Rev Chil Pediatr. 2008;79:26-35. https:\/\/doi.org\/10.4067\/S0370-41062008000100004","DOI":"10.4067\/S0370-41062008000100004"},{"key":"109346","doi-asserted-by":"crossref","unstructured":"Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: A national population based study in the UK and Ireland. Clin Endocrinol (Oxf). 2010;72:358-63. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03717.x","DOI":"10.1111\/j.1365-2265.2009.03717.x"},{"key":"109347","doi-asserted-by":"crossref","unstructured":"Tun\u00e7 S, K\u00f6pr\u00fcl\u00fc \u00d6, Orta\u00e7 H, Nalbanto\u011flu \u00d6, Dizdarer C, Demir K, et al. Long-term monitoring of Graves\u2019 disease in children and adolescents: A single-center experience. Turkish J Med Sci. 2019;49:464-71. https:\/\/doi.org\/10.3906\/sag-1804-177","DOI":"10.3906\/sag-1804-177"},{"key":"109348","doi-asserted-by":"crossref","unstructured":"Kourime M, McGowan S, Al Towati M, Ahmed SF, Stewart G, Williamson S, et al. Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: The case for long-term antithyroid treatment and the importance of initial counselling. Arch Dis Child. 2018;103:637-42. https:\/\/doi.org\/10.1136\/archdischild-2017-313454","DOI":"10.1136\/archdischild-2017-313454"},{"key":"109349","doi-asserted-by":"crossref","unstructured":"Okawa ER, Grant FD, Smith JR. Pediatric Graves\u2019 disease: Decisions regarding therapy. Curr Opin Pediatr. 2015;27:442-7. https:\/\/doi.org\/10.1097\/MOP.0000000000000241","DOI":"10.1097\/MOP.0000000000000241"},{"key":"109350","doi-asserted-by":"crossref","unstructured":"Sims EK, Eugster EA, Nebesio TD. Detours on the road to diagnosis of graves disease. Clin Pediatr (Phila). 2012;51:160-4. https:\/\/doi.org\/10.1177\/0009922811418823","DOI":"10.1177\/0009922811418823"},{"key":"109351","doi-asserted-by":"crossref","unstructured":"Goldstein SM, Katowitz WR, Moshang T, Katowitz JA. Pediatric thyroid-associated orbitopathy: The children\u2019s hospital of philadelphia experience and literature review. Thyroid. 2008;18:997-9. https:\/\/doi.org\/10.1089\/thy.2008.0014","DOI":"10.1089\/thy.2008.0014"},{"key":"109352","doi-asserted-by":"crossref","unstructured":"Ladd JM, Sabsabi B, von Oettingen JE. Thyroid storm in a toddler presenting as a febrile seizure. Pediatrics. 2020;145:e20191920. https:\/\/doi.org\/10.1542\/peds.2019-1920","DOI":"10.1542\/peds.2019-1920"},{"key":"109353","doi-asserted-by":"crossref","unstructured":"Esen \u0130, Bayramo\u011flu E, Yildiz M, Aydin M, \u00d6zturhan EK, Aycan Z, et al. Management of thyrotoxicosis in children and adolescents: A Turkish multi-center experience. J Clin Res Pediatr Endocrinol. 2019;11:164-72. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2018.2018.0210","DOI":"10.4274\/jcrpe.galenos.2018.2018.0210"},{"key":"109354","doi-asserted-by":"crossref","unstructured":"Yap PS, Ali O, Truran P, Aspinall S. Thyrotoxicosis and thyroiditis. Surgery. 2020;38:794-800. https:\/\/doi.org\/10.1016\/j.mpsur.2020.10.002","DOI":"10.1016\/j.mpsur.2020.10.002"},{"key":"109355","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence. Best Pract Res Clin Endocrinol Metab. 2018;32:373-86. https:\/\/doi.org\/10.1016\/j.beem.2018.03.014","DOI":"10.1016\/j.beem.2018.03.014"},{"key":"109356","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich E, Wahl R. Thyroid autoimmunity: Role of anti-thyroid antibodies in thyroid and extrathyroidal diseases. Front Immunol. 2017;8:521. https:\/\/doi.org\/10.3389\/fimmu.2017.00521","DOI":"10.3389\/fimmu.2017.00521"},{"key":"109357","doi-asserted-by":"crossref","unstructured":"Comit\u00e9 Nacional de Endocrinolog\u00eda. Alteraciones tiroideas en la infancia y en la adolescencia. Parte 2: hipotiroidismo. Arch Argent Pediatr. 2021;119:S8-16.","DOI":"10.5546\/aap.2021.s8"},{"key":"109358","doi-asserted-by":"crossref","unstructured":"Malik SA. Comparison between peak systolic velocity of the inferior thyroid artery and technetium-99m pertechnetate thyroid uptake in differentiating Graves\u2019 disease from thyroiditis. Arch Endocrinol Metab. 2019;63:495-500. https:\/\/doi.org\/10.20945\/2359-3997000000165","DOI":"10.20945\/2359-3997000000165"},{"key":"109359","doi-asserted-by":"crossref","unstructured":"Perdomo CM, Garc\u00eda-Go\u00f1i M, Sancho L, JJ Paricio, Lozano MD, de la Higuera M, et al. Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis. Clin Endocrinol (Oxf). 2021;94:466-72. https:\/\/doi.org\/10.1111\/cen.14308","DOI":"10.1111\/cen.14308"},{"key":"109360","doi-asserted-by":"crossref","unstructured":"Marques O, Antunes A, Oliveira MJ. Treatment of Graves\u2019 disease in children: The Portuguese experience. Endocrinol Diabetes y Nutr. 2018;65:143-9. https:\/\/doi.org\/10.1016\/j.endinu.2017.11.014","DOI":"10.1016\/j.endinu.2017.11.014"},{"key":"109361","doi-asserted-by":"crossref","unstructured":"Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term methimazole therapy in Juvenile Graves\u2019 Disease: A randomized trial. Pediatrics. 2019;143:e20183034. https:\/\/doi.org\/10.1542\/peds.2018-3034","DOI":"10.1542\/peds.2018-3034"},{"key":"109362","doi-asserted-by":"crossref","unstructured":"Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves\u2019 disease in children. Int J Pediatr Endocrinol. 2010;2010:1-4. https:\/\/doi.org\/10.1155\/2010\/176970","DOI":"10.1155\/2010\/176970"},{"key":"109363","doi-asserted-by":"crossref","unstructured":"Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, et al. Antithyroid drug treatment for Graves\u2019 disease in children: A long-term retrospective study at a single institution. Thyroid. 2014;24:200-7. https:\/\/doi.org\/10.1089\/thy.2012.0612","DOI":"10.1089\/thy.2012.0612"},{"key":"109364","doi-asserted-by":"crossref","unstructured":"Yasuda K, Miyoshi Y, Tachibana M, Namba N, Miki K, Nakata Y, et al. Relationship between dose of antithyroid drugs and adverse events in pediatric patients with graves\u2019 disease. Clin Pediatr Endocrinol. 2017;26:1-7. https:\/\/doi.org\/10.1297\/cpe.26.1","DOI":"10.1297\/cpe.26.1"},{"key":"109365","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, Coutant R, et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: National long-term cohort study. J Clin Endocrinol Metab. 2012;97:110-9. https:\/\/doi.org\/10.1210\/jc.2011-1944","DOI":"10.1210\/jc.2011-1944"},{"key":"109366","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Oliver I, Rodrigue D, Lambert AS, Coutant R. Graves\u2019 disease in children. Ann Endocrinol (Paris). 2018;79:647-55. https:\/\/doi.org\/10.1016\/j.ando.2018.08.001","DOI":"10.1016\/j.ando.2018.08.001"},{"key":"109367","doi-asserted-by":"crossref","unstructured":"De Luca F, Valenzise M. Controversies in the pharmacological treatment of Graves\u2019 disease in children. Expert Rev Clin Pharmacol. 2018;11:1113-21. https:\/\/doi.org\/10.1080\/17512433.2018.1546576","DOI":"10.1080\/17512433.2018.1546576"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/6244\/5059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/6244\/5059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T20:19:18Z","timestamp":1660249158000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/6244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.6244","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"type":"electronic","value":"2590-7379"},{"type":"print","value":"0120-4157"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"2022-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Presentaci\u00f3n de caso","name":"content_type","label":"Content Type"}]}}